Country: Germany
Language: English
Source: HMA (Heads of Medicines Agencies)
erysipelothrix rhusiopathiae 1 ppd, porcine parvovirus 9 log2HI units
Intervet Intenational BV
QI09AL01
Suspension for injection
inactivated Porcine parvovirus vaccine + inactivated Erysipelothrix vaccine
Pigs Other
2012-02-28
Porcilis Ery+Parvo renew al SPC-Labelling-Leaflet (DE/V/0233/001/R/001) d90 _ _ _ _ SUMMARY OF PRODUCT CHARACTERISTICS Porcilis Ery+Parvo renew al SPC-Labelling-Leaflet (DE/V/0233/001/R/001) d90 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis Ery+Parvo 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCES: Per dose of 2 ml: - Inactivated PPV strain 014: inducing at least 9 log 2 HI units as measured in the guinea pig potency test - Inactivated lysed antigen concentrate of Erysipelothrix rhusiopathiae strain M2 (serotype 2): 1 pig protective dose (ppd) as measured in the Ph. Eur. potency test ADJUVANT: dl- -tocopherol: 150 mg EXCIPIENT: 0.02 - 0.05% formaldehyde For a list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs (Sows and Gilts). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIE S For active immunization of sows and gilts to prevent clinical signs of Erysipelas disease caused by all relevant _Erysipelothrix rhusiopathiae_ serotypes (serotype 1 and 2) and for protection against embryonal and fetal death caused by porcine parvovirus infection. E. rhusiopathiae: Onset of immunity 3 weeks Duration of immunity: 6 months PPV: Duration of immunity 12 months 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS Porcilis Ery+Parvo renew al SPC-Labelling-Leaflet (DE/V/0233/001/R/001) d90 None. Porcilis Ery+Parvo renew al SPC-Labelling-Leaflet (DE/V/0233/001/R/001) d90 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Sick and weak animals should not be vaccinated. SP Read the complete document